-
-
-
-
-
-
-
Piper Sandler on Kymera Therapeutics (KYMR): 'All Eyes on BroADen2 Data in 4Q'
-
-
-
-
-
-
-
Deutsche Bank Starts Kymera Therapeutics (KYMR) at Hold
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Kymera Therapeutics (KYMR) Following Sector Deal
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) Tops Q1 EPS by 17c
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley
-
-
-
-
-
-
-
Kymera Therapeutics outlines 2026 clinical trial plans
-
-
-
-
-
-
-
Kymera Therapeutics (KYMR) PT Raised at Piper Sandler Following Positive BroADen Data
-
474,153 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


